Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

The medical community has former governor Rick Perry to thank for a major stride in regenerative medicine.

"He had just gotten elected for the last time and he wanted to leave a legacy. He was tired of people going to Japan or Germany when they needed stem cells," recalls David Eller, chairman, co-founder and CEO of Celltex.

That was 2011, the year that the former president of Dupont Pharmeceuticals-Europe and orthopedic surgeon Dr. Stanley Jones incorporated as Celltex. Perry got the law passed to make it legal to harvest his stem cells, and Jones implanted them while the governor was under the knife for a spinal fusion surgery.

Perry resigned from the Celltex board in 2017, but the truth is, the company no longer needed his clout. Just a year after its debut, the company had in excess of 200 clients, each paying a banking enrollment fee of $6,500. Now, there are close to 1,300.

From research to recovery
Eller is originally from Houston, and he says his hometown is the ideal home base for the company, with its access to the world's largest medical center. The Galleria-area office and lab employ 35 people, with about 50 workers worldwide.

Close to the same time that his friend Perry received his stem cells, Eller also had the treatment in hopes of resolving pain from a college football injury.

"I would go to work and put four to six Advil in my pocket," the CEO recalls.

Within months, all of them remained in his pocket.

But others have had even more dramatic results. Celltex checks in with patients three, six and nine months after their treatments to find out how they're doing. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

Implementation and the FDA
Celltex's chief scientific officer, Dr. Jane Young, co-authored a study of two severe juvenile rheumatoid arthritis patients whose conditions didn't respond to standard treatments. After trying stem cells, both reported marked improvement in autonomic nervous system and immune function.

Stem cells are gathered through a patient's fat, which can be extracted at any of the 80 facilities around the country that partner with Celltex. The fat is processed at the Houston lab, where processing takes 30 to 35 days.

"We have 15 billion cells in process each day," says Erik Eller, the company's vice president of operations, clarifying that some clients' cells grow faster than others'.

It takes 14 days to come out of cryostasis and leave the lab. From there, the stem cells travel to Hospital Galenia in Cancun, Mexico for implantation, since the FDA categorizes stem cells as a drug if they have expanded as they do at Celltex. That means that a patient cannot use his own stem cells in the United States without a clinical trial. To circumnavigate the red tape, Celltex has simply partnered with the luxurious Mexican hospital.

This is currently the company's biggest challenge, says David Eller, but one he expects to overcome.

"We have very good relations with the US FDA," he says. "They are very interested in what we know. Our approach is really is very progressive and we've grown every year."

Ultimately, Eller hopes to be able to implant stem cells in the United States. But the company's foreign growth is a good start. Celltex is now operating in the Bahamas and is hoping to add Australian extraction facilities sometime this year. They are also in negotiations with a team from Saudi Arabia interested in expanding Celltex to the Middle East.

Other goals for Celltex include improvements both in the realms of sales and revenue and streamlining and improving the safety and efficacy of treatment. Research collaborations with Baylor College of Medicine and Texas A&M will help with the company's medical credibility. This all may help to convince the FDA to allow the Celltex to get a biologics license, the final proof that it is not a drug company. But no matter how it's categorized, Celltex is growing exponentially as its cells.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

space funding

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, has secured a $9.8 million Phase Two government contract for its orbital transfer vehicle.

The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company.

Intuitive Machine's orbital transfer vehicle (OTV) is designed to transfer payloads between Earth's orbit and the Moon and is built around the company's Nova-C lander, which has been a part of two successful lunar missions.

“Our OTV is a direct evolution of our lunar surface delivery missions—positioning us to expand into the rapidly growing market for in-space logistics,” Steve Altemus, Intuitive Machines CEO, said in the release. “We’re leveraging our flight-proven technology to operate a mission-ready service that delivers customer payloads across orbits—from Earth to the Moon and beyond.”

The company says the fast, flexible vehicle could be used for orbital servicing, logistics and communications in medium earth orbit, low lunar orbit and a variety of other destinations.

Intuitive Machines expects to begin manufacturing and flight integration as soon as 2026, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations."

The company has received millions from NASA for its lunar rover, lunar lander, science and technology payloads, and communications and navigation services over the years. It also recently landed up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab from Texas's Space Exploration and Research Fund.

Earlier this month, the City of Houston agreed to add three acres of commercial space for Intuitive Machines at the Houston Spaceport at Ellington Airport. Read more here.

Houston tech jobs to grow in 2025 as Texas leads U.S. in new tech employment

by the numbers

Tech employment in the Houston metro area is expected to climb by more than two percent this year, according to a new projection.

CompTIA’s State of the Tech Workforce 2025 report forecasts the Houston area will employ 158,176 tech professionals this year, compared with an estimated 154,905 last year. That would be an increase of 2.1 percent.

These numbers take into account tech workers across all industries, not just those employed in the tech sector. Many of these professionals do work in the tech sector (40 percent), with the remainder (60 percent) employed in other sectors.

Even more impressive than the year-to-year increase is the jump in Houston-area tech employment from 2019 to 2025. During that period, tech employment grew 16.6 percent, according to the report.

The Houston area ranks eighth among major metro areas for the number of tech jobs expected to be added this year (3,271). Dallas rises to No. 1 for the most jobs expected to be added (projection of 13,997 new tech jobs in 2025), with Austin at No. 5 (7,750 new jobs) and San Antonio at No. 21 (1,617 new jobs).

On a state-by-state basis, Texas ranks first for the number of tech workers projected to be added this year (40,051)—up significantly from the 8,181 jobs estimated to be added in 2024—and second for the size of the tech workforce last year (972,747), the report says. The Lone Star State lands at No. 4 for the highest percentage (24 percent) of tech jobs expected to be added from 2025 to 2035.

Backed by a nearly $1.4 billion commitment from the state, the semiconductor industry is helping propel the growth of tech jobs in Houston and throughout Texas.

In 2023, the state launched the Texas Semiconductor Innovation Fund. The fund provides incentives to encourage semiconductor research, design and manufacturing in Texas. State lawmakers allocated $698.3 million for the fund. Another $660 million in state money will help establish semiconductor research and development centers at the University of Texas at Austin and Texas A&M University.

“Texas has the innovation, the infrastructure, and the talent to continue to lead the American resurgence in critical semiconductor manufacturing and the technologies of tomorrow,” Gov. Greg Abbott said in a release.

The Houston area is benefiting from the semiconductor boom.

For example, chip manufacturer Nvidia and electronics maker Foxconn plan to build a factory in Houston that will produce AI supercomputers.

Nvidia said in April that the AI supercomputers “are the engines of a new type of data center created for the sole purpose of processing artificial intelligence — AI factories that are the infrastructure powering a new AI industry.”

Meanwhile, tech giant Apple plans to open a 250,000-square-foot factory in Houston that will manufacture servers for its data centers in support of Apple’s AI business. The Houston plant is part of a four-year, $500 million nationwide expansion that Apple unveiled in February.